| Literature DB >> 30034854 |
Anamika Chatterjee1, Christina Feldmann1, Jasmin S Hanke1, Marcel Ricklefs1, Malakh Shrestha1, Guenes Dogan1, Axel Haverich1, Jan D Schmitto1.
Abstract
Left ventricular assist devices (LVADs) are emerging as the treatment of choice for advanced heart failure due to the dearth of healthy donor hearts for cardiac transplantation. The HeartMate 3 LVAD is a novel centrifugal pump which was developed to provide hemodynamic support in heart failure patients, either as a bridge to transplant (BTT), myocardial recovery, or as destination therapy (DT). Technological and clinical advancements have led to optimized hemocompatibility and development of less invasive surgical procedures for the implantation of this pump. The worldwide first implantation of the HeartMate 3 was performed by Prof. Schmitto and his team at Hannover Medical School, Germany in 2014, paving the way for subsequent surgical developments. This article summarizes the advanced technological and clinical aspects of the HeartMate 3 and outlines future technical developments for safe and effective treatment of advanced heart failure.Entities:
Keywords: Centrifugal pump; HeartMate 3; left ventricular assist device (LVAD)
Year: 2018 PMID: 30034854 PMCID: PMC6035956 DOI: 10.21037/jtd.2017.10.124
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895